{"database":"ENA","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Genomics"],"center_name":["Schober Lab, Mikrobiologisches Institut - Klinische Mikrobiologie, Immunologie und Hygiene, Friedrich-Alexander-Universität Erlangen-Nürnberg"],"full_dataset_link":["https://www.ebi.ac.uk/ena/browser/view/PRJNA843995"],"scientific_name":["Homo sapiens"],"long_description":["T cell receptor (TCR) avidity is assumed to be a major determinant of the spatiotemporal fate and protective capacity of tumor-specific T cells. However, monitoring polyclonal T cell responses with known TCR avidities in vivo over space and time remains challenging. Here, we investigated the fate and functionality of tumor neoantigen-specific T cells with TCRs of distinct avidities in a well-established, reductionist preclinical tumor model and human melanoma patients. Surprisingly, we found that both high- and low-avidity T cells are similarly abundant within the tumor and adopt concordant phenotypic signs of exhaustion. Outside the tumor, high-avidity TCR T cells were also not generally overrepresented, but instead selectively enriched in T cell populations with intermediate PD-1 protein expression or corresponding RNA and surface protein signatures of recent activation. Tumor-reactive TCRs with high protective capacity circulating in peripheral blood are therefore characterized by a signature of recent activation. Overall design: scRNA sequencing data for antigen specific cells before and after TIL infusion and from the infusion product of melanoma patients"],"tag":["xref:PubMed:35960818"],"repository":["ENA"],"additional_accession":[]},"is_claimable":false,"name":"Signatures of recent activation identify a circulating T cell compartment containing tumor-specific antigen receptors with high avidity","description":"Signatures of recent activation identify a circulating T cell compartment containing tumor-specific antigen receptors with high avidity","dates":{"last_updated":"2025-09-24","first_public":"2022-06-04"},"accession":"PRJNA843995","cross_references":{"GEO":["GSE205145"],"taxon":["9606"],"PubMed":["35960818"]}}